Acalabrutinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11703 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 18 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | lymphoma, non-Hodgkin, familial | KG + DL |
| 2 | colon adenocarcinoma | KG + DL |
| 3 | small intestinal Burkitt lymphoma | KG + DL |
| 4 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 5 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 6 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 7 | tonsillar lymphoma | KG + DL |
| 8 | neoplasm of mature B-cells | KG + DL |
| 9 | lymph node cancer | KG + DL |
| 10 | polyclonal hypergammaglobulinemia | KG + DL |
| 11 | chest wall lymphoma | KG + DL |
| 12 | lymphoma | KG + DL |
| 13 | follicular lymphoma | KG + DL |
| 14 | monoclonal paraproteinemia disease | KG + DL |
| 15 | interdigitating dendritic cell sarcoma | KG + DL |
| 16 | follicular lymphoma, susceptibility to, 1 | KG + DL |
| 17 | subcutaneous panniculitis-like T-cell lymphoma | KG + DL |
| 18 | plasmacytoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.